INmune Bio
INMB
57 hedge funds and large institutions have $40.3M invested in INmune Bio in 2024 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 16 increasing their positions, 11 reducing their positions, and 14 closing their positions.
55% more call options, than puts
Call options by funds: $765K | Put options by funds: $492K
45% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 11
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
25% more capital invested
Capital invested by funds: $32.2M → $40.3M (+$8.1M)
10% more funds holding
Funds holding: 52 → 57 (+5)
7.89% more ownership
Funds ownership: 15.21% → 23.1% (+7.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$5.88M |
| 2 |
BlackRock
New York
|
+$5.65M |
| 3 |
PP
Praetorian PR
Rincon,
Puerto Rico
|
+$4.78M |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$2.24M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
-$1.18M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.1M |
| 3 |
Jane Street
New York
|
-$869K |
| 4 |
Goldman Sachs
New York
|
-$749K |
| 5 |
Millennium Management
New York
|
-$656K |
INMB Hedge Fund Activity: Q2 2024 in Review
57 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in INmune Bio (INMB) for Q2 2024, worth a combined $40.3M — up 25% from $32.2M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new INMB positions and 14 closed out — a net gain of 5 holders — while 16 added to existing stakes and 11 trimmed.
The largest buyer was CVI Holdings, opening a new position worth an estimated $5.88M. The largest seller was Janney Montgomery Scott, cutting an estimated $1.18M.
- 57 institutional investors held INmune Bio (INMB) as of Q2 2024, up from 52 in Q1 2024.
- Funds reported $40.3M of INmune Bio stock for Q2 2024, up 25% quarter-over-quarter.
- 19 funds opened new INmune Bio positions in Q2 2024 and 14 closed out, a net change of +5 holders.
- The largest INmune Bio buyer in Q2 2024 was CVI Holdings, an estimated $5.88M added.
- The largest INmune Bio seller in Q2 2024 was Janney Montgomery Scott, an estimated $1.18M sold.
Based on aggregated 13F filings for Q2 2024.